Last reviewed · How we verify
Peginterferon alpha — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Peginterferon alpha (Peginterferon alpha) — Merck Sharp & Dohme LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Peginterferon alpha TARGET | Peginterferon alpha | Merck Sharp & Dohme LLC | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Peginterferon alpha CI watch — RSS
- Peginterferon alpha CI watch — Atom
- Peginterferon alpha CI watch — JSON
- Peginterferon alpha alone — RSS
Cite this brief
Drug Landscape (2026). Peginterferon alpha — Competitive Intelligence Brief. https://druglandscape.com/ci/peginterferon-alpha. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab